Structure-Based Drug Discovery of <i>N</i> -(( <i>R</i> )-3-(7-Methyl-1 <i>H</i> -indazol-5-yl)-1-oxo-1-((( <i>S</i> )-1-oxo-3-(piperidin-4-yl)-1-(4-(pyridin-4-yl)piperazin-1-yl)propan-2-yl)amino)propan-2-yl)-2′-oxo-1′,2′-dihydrospiro[piperidine-4,4′-pyrido[2,3- <i>d</i> ][1,3]oxazine]-1-carboxamide (HTL22562): A Calcitonin Gene-Related Peptide Receptor Antagonist for Acute Treatment of Migraine

Abstract

Structure-based drug design enabled the discovery of <b>8</b>, HTL22562, a calcitonin gene-related peptide (CGRP) receptor antagonist. The structure of <b>8</b> complexed with the CGRP receptor was determined at a 1.6 Å resolution. Compound <b>8</b> is a highly potent, selective, metabolically stable, and soluble compound suitable for a range of administration routes that have the potential to provide rapid systemic exposures with resultant high levels of receptor coverage (e.g., subcutaneous). The low lipophilicity coupled with a low anticipated clinically efficacious plasma exposure for migraine also suggests a reduced potential for hepatotoxicity. These properties have led to <b>8</b> being selected as a clinical candidate for acute treatment of migraine.